{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:16:10Z","timestamp":1791000970350,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81774214"],"award-info":[{"award-number":["No. 81774214"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Altern Med"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Astragaloside IV (AS-IV) was reported to play a role in improving diabetic nephropathy (DN), however, the underlying mechanisms still remain unclear. The aim of the present study is to investigate whether AS-IV ameliorates DN via the regulation of endothelial nitric oxide synthase (eNOS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>DN model was induced in Sprague-Dawley (SD) male rats by intraperitoneal injection of 65\u2009mg\/kg streptozotocin (STZ). Rats in the AS-IV treatment group were orally gavaged with 5\u2009mg\/kg\/day or 10\u2009mg\/kg\/day AS-IV for eight consecutive weeks. Body weight, blood glucose, blood urea nitrogen (BUN), Serum creatinine (Scr), proteinuria and Glycosylated hemoglobin (HbA1c) levels were measured. Hematoxylin-Eosin (HE) and Periodic Acid-Schiff (PAS) staining were used to detect the renal pathology. The apoptosis status of glomerular cells was measured by TUNEL assay. The phosphorylation and acetylation of eNOS were detected by western blot. The effects of AS-IV on high-glucose (HG)-induced apoptosis and eNOS activity were also investigated in human renal glomerular endothelial cells (HRGECs) in vitro.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment with AS-IV apparently reduced DN symptoms in diabetic rats, as evidenced by reduced BUN, Scr, proteinuria, HbA1c levels and expanding mesangial matrix. AS-IV treatment also promoted the synthesis of nitric oxide (NO) in serum and renal tissues and ameliorated the phosphorylation of eNOS at Ser 1177 with decreased eNOS acetylation. Moreover, HG-induced dysfunction of HRGECs including increased cell permeability and apoptosis, impaired eNOS phosphorylation at Ser 1177, and decreased NO production, were all reversed by AS-IV treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These novel findings suggest that AS-IV ameliorates functional abnormalities of DN through inhibiting acetylation of eNOS and activating its phosphorylation at Ser 1177. AS-IV could be served as a potential therapeutic drug for DN.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12906-019-2728-9","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T17:17:04Z","timestamp":1575566224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Astragaloside IV protects against diabetic nephropathy via activating eNOS in streptozotocin diabetes-induced rats"],"prefix":"10.1186","volume":"19","author":[{"given":"Yuyan","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"issue":"2","key":"2728_CR1","first-page":"RA37","volume":"16","author":"FA Hakim","year":"2010","unstructured":"Hakim FA, Pflueger A. Role of oxidative stress in diabetic kidney disease. Med Sci Monit. 2010;16(2):RA37\u201348.","journal-title":"Med Sci Monit"},{"issue":"1","key":"2728_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1681\/ASN.2004080648","volume":"16","author":"MD Breyer","year":"2005","unstructured":"Breyer MD, Bottinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, Sharma K. Amdcc: mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005;16(1):27\u201345.","journal-title":"J Am Soc Nephrol"},{"key":"2728_CR3","doi-asserted-by":"publisher","first-page":"590541","DOI":"10.1155\/2014\/590541","volume":"2014","author":"T Takahashi","year":"2014","unstructured":"Takahashi T, Harris RC. Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice. J Diabetes Res. 2014;2014:590541.","journal-title":"J Diabetes Res"},{"issue":"1","key":"2728_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/path.1250","volume":"199","author":"EW Albrecht","year":"2003","unstructured":"Albrecht EW, Stegeman CA, Heeringa P, Henning RH, van Goor H. Protective role of endothelial nitric oxide synthase. J Pathol. 2003;199(1):8\u201317.","journal-title":"J Pathol"},{"issue":"13","key":"2728_CR5","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1161\/CIRCULATIONAHA.108.835223","volume":"120","author":"J Xu","year":"2009","unstructured":"Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009;120(13):1266\u201386.","journal-title":"Circulation"},{"issue":"1","key":"2728_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/ncpendmet0366","volume":"3","author":"C Rask-Madsen","year":"2007","unstructured":"Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007;3(1):46\u201356.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"4","key":"2728_CR7","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/ndt\/gfm797","volume":"23","author":"B Hohenstein","year":"2008","unstructured":"Hohenstein B, Hugo CP, Hausknecht B, Boehmer KP, Riess RH, Schmieder RE. Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrol Dial Transplant. 2008;23(4):1346\u201354.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"2728_CR8","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1681\/ASN.2006070798","volume":"17","author":"HJ Zhao","year":"2006","unstructured":"Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, Fogo AB, Breyer MD, Harris RC. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol. 2006;17(10):2664\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2728_CR9","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1093\/ndt\/gfn174","volume":"23","author":"R Komers","year":"2008","unstructured":"Komers R, Anderson S. Glomerular endothelial NOS (eNOS) expression in type 2 diabetic patients with nephropathy. Nephrol Dial Transplant. 2008;23(9):3037 author reply 3037-3038.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"2728_CR10","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.2337\/diabetes.54.9.2628","volume":"54","author":"Z Qi","year":"2005","unstructured":"Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB, Breyer MD. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes. 2005;54(9):2628\u201337.","journal-title":"Diabetes"},{"issue":"8","key":"2728_CR11","doi-asserted-by":"publisher","first-page":"e0182558","DOI":"10.1371\/journal.pone.0182558","volume":"12","author":"X Liu","year":"2017","unstructured":"Liu X, Wang W, Song G, Wei X, Zeng Y, Han P, Wang D, Shao M, Wu J, Sun H, et al. Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network. PLoS One. 2017;12(8):e0182558.","journal-title":"PLoS One"},{"issue":"3","key":"2728_CR12","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.cyto.2013.01.008","volume":"61","author":"D Gui","year":"2013","unstructured":"Gui D, Huang J, Guo Y, Chen J, Chen Y, Xiao W, Liu X, Wang N. Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-kappaB-mediated inflammatory genes expression. Cytokine. 2013;61(3):970\u20137.","journal-title":"Cytokine"},{"issue":"6","key":"2728_CR13","doi-asserted-by":"publisher","first-page":"e39824","DOI":"10.1371\/journal.pone.0039824","volume":"7","author":"D Gui","year":"2012","unstructured":"Gui D, Guo Y, Wang F, Liu W, Chen J, Chen Y, Huang J, Wang N. Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo. PLoS One. 2012;7(6):e39824.","journal-title":"PLoS One"},{"issue":"10","key":"2728_CR14","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1177\/1535370214532597","volume":"239","author":"L Wang","year":"2014","unstructured":"Wang L, Chi YF, Yuan ZT, Zhou WC, Yin PH, Zhang XM, Peng W, Cai H. Astragaloside IV inhibits renal tubulointerstitial fibrosis by blocking TGF-beta\/Smad signaling pathway in vivo and in vitro. Exp Biol Med. 2014;239(10):1310\u201324.","journal-title":"Exp Biol Med"},{"issue":"6","key":"2728_CR15","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1159\/000362974","volume":"33","author":"Y Chen","year":"2014","unstructured":"Chen Y, Gui D, Chen J, He D, Luo Y, Wang N. Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats. Cell Physiol Biochem. 2014;33(6):1975\u201387.","journal-title":"Cell Physiol Biochem"},{"key":"2728_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3389\/fphar.2016.00500","volume":"7","author":"H Guo","year":"2016","unstructured":"Guo H, Cao A, Chu S, Wang Y, Zang Y, Mao X, Wang H, Liu C, Zhang X, Peng W. Astragaloside IV attenuates Podocyte apoptosis mediated by endoplasmic reticulum stress through Upregulating Sarco\/endoplasmic reticulum Ca (2+)-ATPase 2 expression in diabetic nephropathy. Front Pharmacol. 2016;7:500.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2728_CR17","first-page":"1078","volume":"41","author":"KQ He","year":"2018","unstructured":"He KQ, Li WZ, Chai XQ, Yin YY, Jiang Y, Li WP. Astragaloside IV prevents kidney injury caused by iatrogenic hyperinsulinemia in a streptozotocininduced diabetic rat model. Int J Mol Med. 2018;41(2):1078\u201388.","journal-title":"Int J Mol Med"},{"issue":"1","key":"2728_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3892\/ijmm.2014.1741","volume":"34","author":"L Sun","year":"2014","unstructured":"Sun L, Li W, Xiong L, Li G, Ma R. Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase\/ROS\/Akt\/NFkappaB pathway under high glucose conditions. Int J Mol Med. 2014;34(1):167\u201376.","journal-title":"Int J Mol Med"},{"issue":"10","key":"2728_CR19","doi-asserted-by":"publisher","first-page":"12809","DOI":"10.3390\/molecules181012809","volume":"18","author":"SG Wang","year":"2013","unstructured":"Wang SG, Xu Y, Chen JD, Yang CH, Chen XH. Astragaloside IV stimulates angiogenesis and increases nitric oxide accumulation via JAK2\/STAT3 and ERK1\/2 pathway. Molecules. 2013;18(10):12809\u201319.","journal-title":"Molecules"},{"issue":"4","key":"2728_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5582\/bst.2014.01081","volume":"8","author":"Y Yin","year":"2014","unstructured":"Yin Y, Qi F, Song Z, Zhang B, Teng J. Ferulic acid combined with astragaloside IV protects against vascular endothelial dysfunction in diabetic rats. Biosci Trends. 2014;8(4):217\u201326.","journal-title":"Biosci Trends"},{"key":"2728_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12933-015-0299-8","volume":"14","author":"M Ding","year":"2015","unstructured":"Ding M, Lei J, Han H, Li W, Qu Y, Fu E, Fu F, Wang X. SIRT1 protects against myocardial ischemia-reperfusion injury via activating eNOS in diabetic rats. Cardiovasc Diabetol. 2015;14:143.","journal-title":"Cardiovasc Diabetol"},{"key":"2728_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.visres.2017.02.011","volume":"139","author":"RA Kowluru","year":"2017","unstructured":"Kowluru RA. Diabetic retinopathy, metabolic memory and epigenetic modifications. Vis Res. 2017;139:30\u20138.","journal-title":"Vis Res"},{"issue":"5","key":"2728_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1055\/s-0032-1331256","volume":"45","author":"YY Fan","year":"2013","unstructured":"Fan YY, Kobori H, Nakano D, Hitomi H, Mori H, Masaki T, Sun YX, Zhi N, Zhang L, Huang W, et al. Aberrant activation of the intrarenal renin-angiotensin system in the developing kidneys of type 2 diabetic rats. Horm Metab Res. 2013;45(5):338\u201343.","journal-title":"Horm Metab Res"},{"issue":"12","key":"2728_CR24","first-page":"3810","volume":"117","author":"DF Higgins","year":"2007","unstructured":"Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest. 2007;117(12):3810\u201320.","journal-title":"J Clin Invest"},{"issue":"6","key":"2728_CR25","doi-asserted-by":"publisher","first-page":"e3011","DOI":"10.1002\/dmrr.3011","volume":"34","author":"X Bao","year":"2018","unstructured":"Bao X, Gu Y, Zhang Q, Liu L, Meng G, Wu H, Xia Y, Shi H, Wang H, Sun S, et al. Low serum creatinine predicts risk for type 2 diabetes. Diabetes Metab Res Rev. 2018;34(6):e3011.","journal-title":"Diabetes Metab Res Rev"},{"key":"2728_CR26","doi-asserted-by":"publisher","first-page":"8379327","DOI":"10.1155\/2017\/8379327","volume":"2017","author":"S Fakhruddin","year":"2017","unstructured":"Fakhruddin S, Alanazi W, Jackson KE. Diabetes-induced reactive oxygen species: mechanism of their generation and role in renal injury. J Diabetes Res. 2017;2017:8379327.","journal-title":"J Diabetes Res"},{"key":"2728_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.lfs.2018.05.037","volume":"206","author":"X Lei","year":"2018","unstructured":"Lei X, Zhang BD, Ren JG, Luo FL. Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378\/TRAF5 signaling pathway. Life Sci. 2018;206:77\u201383.","journal-title":"Life Sci"},{"key":"2728_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejphar.2014.04.037","volume":"736","author":"J Chen","year":"2014","unstructured":"Chen J, Chen Y, Luo Y, Gui D, Huang J, He D. Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats. Eur J Pharmacol. 2014;736:86\u201394.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2728_CR29","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.4238\/2015.May.22.12","volume":"14","author":"WS Lu","year":"2015","unstructured":"Lu WS, Li S, Guo WW, Chen LL, Li YS. Effects of Astragaloside IV on diabetic nephropathy in rats. Genet Mol Res. 2015;14(2):5427\u201334.","journal-title":"Genet Mol Res"},{"key":"2728_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12882-015-0031-7","volume":"16","author":"ZS Wang","year":"2015","unstructured":"Wang ZS, Xiong F, Xie XH, Chen D, Pan JH, Cheng L. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress. BMC Nephrol. 2015;16:44.","journal-title":"BMC Nephrol"},{"issue":"5","key":"2728_CR31","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1172\/JCI117557","volume":"94","author":"M Ziche","year":"1994","unstructured":"Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P, Ledda F. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest. 1994;94(5):2036\u201344.","journal-title":"J Clin Invest"},{"issue":"18","key":"2728_CR32","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1161\/01.CIR.0000093190.53478.78","volume":"108","author":"T Namba","year":"2003","unstructured":"Namba T, Koike H, Murakami K, Aoki M, Makino H, Hashiya N, Ogihara T, Kaneda Y, Kohno M, Morishita R. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation. 2003;108(18):2250\u20137.","journal-title":"Circulation"},{"issue":"6","key":"2728_CR33","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1046\/j.1523-1755.2000.00422.x","volume":"58","author":"YG Kim","year":"2000","unstructured":"Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, Gordon KL, Matsui K, Breiteneder-Geleff S, Shankland SJ, Hughes J, et al. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int. 2000;58(6):2390\u20139.","journal-title":"Kidney Int"},{"issue":"7","key":"2728_CR34","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1681\/ASN.V1271448","volume":"12","author":"DH Kang","year":"2001","unstructured":"Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol. 2001;12(7):1448\u201357.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2728_CR35","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/ki.2012.248","volume":"82","author":"H Cheng","year":"2012","unstructured":"Cheng H, Wang H, Fan X, Paueksakon P, Harris RC. Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db\/db mice. Kidney Int. 2012;82(11):1176\u201383.","journal-title":"Kidney Int"},{"issue":"4","key":"2728_CR36","doi-asserted-by":"publisher","first-page":"e94540","DOI":"10.1371\/journal.pone.0094540","volume":"9","author":"KS Yang","year":"2014","unstructured":"Yang KS, Lim JH, Kim TW, Kim MY, Kim Y, Chung S, Shin SJ, Choi BS, Kim HW, Kim YS, et al. Vascular endothelial growth factor-receptor 1 inhibition aggravates diabetic nephropathy through eNOS signaling pathway in db\/db mice. PLoS One. 2014;9(4):e94540.","journal-title":"PLoS One"},{"issue":"6736","key":"2728_CR37","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/21218","volume":"399","author":"D Fulton","year":"1999","unstructured":"Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399(6736):597\u2013601.","journal-title":"Nature"},{"issue":"6736","key":"2728_CR38","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/21224","volume":"399","author":"S Dimmeler","year":"1999","unstructured":"Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399(6736):601\u20135.","journal-title":"Nature"},{"issue":"6","key":"2728_CR39","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2337\/db05-1595","volume":"55","author":"R Komers","year":"2006","unstructured":"Komers R, Schutzer WE, Reed JF, Lindsley JN, Oyama TT, Buck DC, Mader SL, Anderson S. Altered endothelial nitric oxide synthase targeting and conformation and caveolin-1 expression in the diabetic kidney. Diabetes. 2006;55(6):1651\u20139.","journal-title":"Diabetes"},{"issue":"4","key":"2728_CR40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1172\/JCI9419","volume":"106","author":"Z Luo","year":"2000","unstructured":"Luo Z, Fujio Y, Kureishi Y, Rudic RD, Daumerie G, Fulton D, Sessa WC, Walsh K. Acute modulation of endothelial Akt\/PKB activity alters nitric oxide-dependent vasomotor activity in vivo. J Clin Invest. 2000;106(4):493\u20139.","journal-title":"J Clin Invest"},{"issue":"5","key":"2728_CR41","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1016\/j.ajpath.2011.01.044","volume":"178","author":"A Advani","year":"2011","unstructured":"Advani A, Huang Q, Thai K, Advani SL, White KE, Kelly DJ, Yuen DA, Connelly KA, Marsden PA, Gilbert RE. Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism. Am J Pathol. 2011;178(5):2205\u201314.","journal-title":"Am J Pathol"},{"issue":"9","key":"2728_CR42","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/01.RES.0000037983.07158.B1","volume":"91","author":"L Rossig","year":"2002","unstructured":"Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U, Zeiher AM, Dimmeler S. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res. 2002;91(9):837\u201344.","journal-title":"Circ Res"},{"issue":"4","key":"2728_CR43","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1002\/jcp.27196","volume":"234","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Dai Y, Liu W, Wang N, Cai Y, Wang S, Zhang F, Liu P, Chen Q, Wang Z. Astragaloside IV enhances taxol chemosensitivity of breast cancer via caveolin-1-targeting oxidant damage. J Cell Physiol. 2019;234(4):4277\u201390.","journal-title":"J Cell Physiol"},{"key":"2728_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lfs.2018.07.053","volume":"209","author":"B Leng","year":"2018","unstructured":"Leng B, Tang F, Lu M, Zhang Z, Wang H, Zhang Y. Astragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4\/NF-kappaB signaling pathway. Life Sci. 2018;209:111\u201321.","journal-title":"Life Sci"}],"container-title":["BMC Complementary and Alternative Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-019-2728-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12906-019-2728-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-019-2728-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T20:09:16Z","timestamp":1665173356000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-019-2728-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2728"],"URL":"https:\/\/doi.org\/10.1186\/s12906-019-2728-9","relation":{},"ISSN":["1472-6882"],"issn-type":[{"value":"1472-6882","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"27 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal experiments in the present study were based on the Guide for the Care and Use of Laboratory Animals and conducted in accordance with the protocol approved by Beijing Tiantan Hospital of Capital Medical University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"355"}}